

# [4 + 2] Cycloaddition of *in Situ* Generated 1,2-Diaza-1,3-dienes with Simple Olefins: Facile Approaches to Tetrahydropyridazines


Xingren Zhong, Jian Lv,\* and Sanzhong Luo\*

Beijing National Laboratory for Molecular Sciences (BNLMS), CAS Key Laboratory of Molecular Recognition and Function, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China


Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300071, China

**S** Supporting Information

**ABSTRACT:** A catalyst-free [4 + 2] annulation process between *in situ* generated 1,2-diaza-1,3-butadienes and simple olefins has been developed. Under mild conditions, the reactions afforded 1,4,5,6-tetrahydropyridazines, which feature a wide range of bioactive compounds, with high yields (up to 99% yield).



Pyridazines and tetrahydropyridazines are versatile structural motifs in a number of natural products (e.g., Pyridazomycin<sup>1</sup> and Azamerone<sup>2</sup>) and pharmaceutically active compounds (Figure 1) such as nonsteroidal progesterone receptor




**Figure 1.** Examples of pyridazine and tetrahydro-pyridazine derivatives in bioactive compounds.


regulators (e.g., **I**),<sup>3</sup> neuro-transmitter inhibitors (e.g., **II**),<sup>4</sup> and influenza neuraminidase inhibitors (e.g., **III**).<sup>5,6</sup> The known synthetic strategies for the tetrahydropyridazines have been limited to a few special substrates,<sup>7,8</sup> and few general methods exist for their synthesis (Scheme 1).<sup>3a,4,5</sup> Strategically, an intermolecular [4 + 2] reaction between 1,2-diaza-1,3-dienes and alkenes is one of the most effective and economic approaches for the synthesis of tetrahydropyridazines (Scheme 1); however, such reactions are limited to those electron-rich alkenes and simple olefins remain challenging substrates.<sup>7</sup> In fact, [4 + 2] cycloaddition with simple olefins, especially for industrial olefins, is generally difficult to achieve and requires harsh conditions and long reaction times.<sup>9–11</sup>

## Scheme 1. General Strategy for Tetrahydropyridazines

Previous strategy:



This work:




Previously, we developed an enantioselective hetero-Diels–Alder reaction of a  $\beta,\gamma$ -unsaturated  $\alpha$ -ketoester with various olefins, including cyclopentadiene,<sup>12a</sup> enol ethers,<sup>12b</sup> and simple olefins,<sup>12c</sup> catalyzed by asymmetric binary acids.<sup>12d</sup> In seeking other electron-deficient dienes for the reactions with simple olefins, we explored 1,2-diaza-1,3-dienes, generated *in situ* from  $\alpha$ -chloro hydrazones, e.g.  $\alpha$ -chloro *N*-benzoyl hydrazone **a1**, as potential targets (Scheme 1). Surprisingly, we found the reactions with olefins proceeded smoothly by simple treatment with a base in the absence of any catalysts. Herein, we present this unprecedented [4 + 2] cycloaddition of 1,2-diaza-1,3-dienes with simple olefins including those industrial olefins, affording 1,4,5,6-tetrahydropyridazines with good to excellent yields.

Initially, we have examined the reaction between **a1** and ethylene (**b1**) in the presence of metal catalysts and no reaction was observed. In this process, it was found that the use of a stoichiometric amount of  $\text{Na}_2\text{CO}_3$  without any catalysts led to the desired adduct **c1** with 46% yield in  $\text{CH}_2\text{Cl}_2$  (Table 1, entry 1). The base-mediated catalyst-free protocol was then optimized in terms of solvents and bases, and the representative

**Received:** February 11, 2015

**Published:** March 4, 2015


Table 1. Optimization of the Reaction Conditions<sup>a</sup>



entry	solvent	base	yield (%) <sup>b</sup>
1	CH <sub>2</sub> Cl <sub>2</sub>	Na <sub>2</sub> CO <sub>3</sub>	46
2	CH <sub>3</sub> CN	Na <sub>2</sub> CO <sub>3</sub>	23
3	Et <sub>2</sub> O	Na <sub>2</sub> CO <sub>3</sub>	trace
4	H <sub>2</sub> O	Na <sub>2</sub> CO <sub>3</sub>	NR
5	CH <sub>2</sub> Cl <sub>2</sub>	CS <sub>2</sub> CO <sub>3</sub>	50
6	CH <sub>2</sub> Cl <sub>2</sub>	K <sub>2</sub> CO <sub>3</sub>	68
7	CH <sub>2</sub> Cl <sub>2</sub>	K <sub>3</sub> PO <sub>4</sub> ·3H <sub>2</sub> O	62
8	CH <sub>2</sub> Cl <sub>2</sub>	Na <sub>3</sub> PO <sub>4</sub> ·12H <sub>2</sub> O	52
9	CH <sub>2</sub> Cl <sub>2</sub>	CH <sub>3</sub> COONa	16
10	CH <sub>2</sub> Cl <sub>2</sub>	DIPEA	13
11	CH <sub>2</sub> Cl <sub>2</sub>	Et <sub>3</sub> N	trace
12	CH <sub>2</sub> Cl <sub>2</sub>	Pyridine	NR
13 <sup>c</sup>	CH <sub>2</sub> Cl <sub>2</sub>	K <sub>2</sub> CO <sub>3</sub>	71
14 <sup>c,d</sup>	CH <sub>2</sub> Cl <sub>2</sub>	K <sub>2</sub> CO <sub>3</sub>	73
15 <sup>c,e</sup>	CH <sub>2</sub> Cl <sub>2</sub>	K <sub>2</sub> CO <sub>3</sub>	47
16 <sup>c,f</sup>	CH <sub>2</sub> Cl <sub>2</sub>	K <sub>2</sub> CO <sub>3</sub>	35
17 <sup>c,g</sup>	CH <sub>2</sub> Cl <sub>2</sub>	K <sub>2</sub> CO <sub>3</sub>	trace

<sup>a</sup>General conditions: **a1** (0.40 mmol), **b1** (16 atm), base (1.0 equiv), solvent (0.1 M), room temperature, 16 h. <sup>b</sup>Determined by <sup>1</sup>H NMR analysis with an internal standard, 1,3,5-trimethoxybenzene. <sup>c</sup>K<sub>2</sub>CO<sub>3</sub> (2.0 equiv). <sup>d</sup>CH<sub>2</sub>Cl<sub>2</sub> (0.2 M). <sup>e</sup>**b1** (10 atm). <sup>f</sup>**b1** (5 atm). <sup>g</sup>**b1** (in balloon). DIPEA = *N,N*-diisopropylethylamine, NR = No reaction

results are summarized in Table 1. First, screening of various solvents was carried out with Na<sub>2</sub>CO<sub>3</sub> (1.0 equiv) at room temperature. The best result was obtained in CH<sub>2</sub>Cl<sub>2</sub> (Table 1, entry 1), whereas others resulted in either low activity or no reaction (Table 1, entry 1 vs entries 2–4). With respect to bases, K<sub>2</sub>CO<sub>3</sub> and K<sub>3</sub>PO<sub>4</sub>·3H<sub>2</sub>O displayed better performance with improved yields (Table 1, entries 6–7), while the use of other inorganic bases resulted in a drop of the yield (Table 1, entries 1, 5, and 8–9). Organic bases, such as DIPEA, Et<sub>3</sub>N, and pyridine, were ineffective (Table 1, entries 10–12). Further increasing the amount of K<sub>2</sub>CO<sub>3</sub> (2.0 equiv) and the concentration of reaction (0.2 M) led to a slight improvement (Table 1, entries 13 and 14). The yield was significantly decreased when reducing the pressure of ethylene **b1** (Table 1, entries 15–17), and dimerization of the *in situ* generated 1,2-diaza-1,3-butadiene was observed under this condition. On the basis of these results, the combination of 0.4 mmol of **a1**, 16 atm of ethylene, and 0.8 mmol of K<sub>2</sub>CO<sub>3</sub> in 2 mL of CH<sub>2</sub>Cl<sub>2</sub> was identified as the optimal reaction conditions.

With the optimized conditions in hand, we next explored the substrate scope of the heterodienes. As shown in Table 2, an array of  $\alpha$ -chloro-*N*-benzoyl hydrazones **a1–11** were tested, resulting in the expected 1,4,5,6-tetrahydropyridazines **c1–11** in good to excellent yields. The significant electronic effect of R<sup>2</sup> on the aromatic ring has been observed. Electron-neutral and -donating groups gave similar results (Table 2, entries 1–3), while electron-withdrawing groups gave relatively lower yields (Table 2, entries 5–6). An *ortho*-substituted derivative such as **a4** also worked well, providing a much better yield than its *para*-substituted counterpart (Table 2, entries 4 vs 5). Gratifyingly, the heteroaromatic 2-thiophene hydrazone **a7** and *N*-tosylhydrazone **a8** could react with ethylene, giving a 51%

Table 2. Substrate Scope for Hydrazones<sup>a</sup>


entry	a	R <sup>1</sup>	R <sup>2</sup>	c	yield (%) <sup>b</sup>
1	<b>a1</b>	Ph	Ph	<b>c1</b>	73
2	<b>a2</b>	Ph	4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	<b>c2</b>	72
3	<b>a3</b>	Ph	4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>c3</b>	78
4	<b>a4</b>	Ph	2-ClC <sub>6</sub> H <sub>4</sub>	<b>c4</b>	79
5	<b>a5</b>	Ph	4-ClC <sub>6</sub> H <sub>4</sub>	<b>c5</b>	58
6	<b>a6</b>	Ph	4-BrC <sub>6</sub> H <sub>4</sub>	<b>c6</b>	40
7	<b>a7</b>	Ph	2-Thiophene	<b>c7</b>	51
8	<b>a8</b>			<b>c8</b>	48
9	<b>a9</b>	4-MeOC <sub>6</sub> H <sub>4</sub>	Ph	<b>c9</b>	56
10	<b>a10</b>	4-ClC <sub>6</sub> H <sub>4</sub>	Ph	<b>c10</b>	93
11	<b>a11</b>	<i>t</i> -Bu	Ph	<b>c11</b>	97


<sup>a</sup>General conditions: **a** (0.40 mmol), **b1** (16 atm), K<sub>2</sub>CO<sub>3</sub> (2.0 equiv) and CH<sub>2</sub>Cl<sub>2</sub> (0.2 M), room temperature, 24 h. <sup>b</sup>Isolated yield.

and 48% yield, respectively (Table 2, entries 7–8). Variations of the R<sup>1</sup> group were also tested, and an electron-withdrawing group was preferred to an electron-donating group (Table 2, entries 9 vs 10). In addition, alkyl substituted hydrazone **a11** worked well, leading to a 97% yield (Table 2, entry 11).

To further expand the substrate scope, we next tested other simple olefins. As seen from Scheme 2, styrenes bearing either electron-donating or -withdrawing moieties could be equally applied in the reaction with the former giving slightly better yields (Scheme 2, **c12–19**). Propylene **b10** and heteroaromatic 2-vinylthiophene **b11** were tolerated with 62% and 91% yields, respectively (**c20** and **c21**).  $\alpha$ -Methylstyrene and 1,1-diphenylethylene could also be incorporated to give acceptable results by increasing the dosage and prolonging the reaction time (**c22** and **c23**). Moreover, norbornene and cyclic dienes such as norbornadiene and cyclopentadiene worked well to give the desired adducts as single diastereoisomers with high yields (**c24**, **c25**, and **c26**). An acyclic diene, isoprene, has also been examined, and the reaction afforded regioisomeric adducts **c27** and **c28** in a 1.6:1 ratio with good yields.

With *p*-methoxy-styrene, we also examined different  $\alpha$ -chloro *N*-acylhydrazones, and the results are shown in Table 3. Hydrazones bearing either electron-donating (Table 3, entries 1–2) or electron-withdrawing groups (Table 3, entries 3–4) could be applied to give good yields. It is worth mentioning that the reaction with alkyl-substituted hydrazone **a12** also proceeded smoothly to give the desired adduct **c33** in 75% yield (Table 3, entry 5).


The developed cycloaddition could be performed on a gram scale. The reaction of  $\alpha$ -chloro *N*-benzoyl hydrazone **a1** with ethylene **b1** afforded **c1** (1.12 g) as a nonsteroidal progesterone receptor regulator<sup>3</sup> in 85% yield (Scheme 3). Treatment of **c1** with LiAlH<sub>4</sub> in THF led to the reduction of the C=O bond, providing benzyl tetrahydropyridazine **d** in 64% yield (Scheme

Scheme 2. Substrate Scope for Simple Alkenes<sup>a,b</sup>

<sup>a</sup>General conditions: **a1** (0.40 mmol), **b** (3.0 equiv),  $K_2CO_3$  (2.0 equiv) and  $CH_2Cl_2$  (0.2 M), room temperature. <sup>b</sup>Isolated yield. <sup>c</sup>Propene **b10** (3 atm) was used. <sup>d</sup>10.0 equiv of olefin were used.



4). Direct hydrogenation of the C=N bond of **c1** could be successfully performed using Pd/C as the catalyst to give the hexahydropyridazine **e** in 78% yield, which could be further converted to a pharmaceutically important 1,4-diamine adduct **f** (Scheme 4).<sup>13</sup> Finally, we focused on the preparation of a pyridazine derivative through an external oxidant. When **c1** was treated with *n*-Bu<sub>4</sub>NI and TBHP in CH<sub>3</sub>CN at room temperature, the desired pyridazine **g** was isolated in 40% yield (Scheme 4).

In summary, we reported herein a mild and catalyst-free [4 + 2] cycloaddition between *in situ* generated 1,2-diaza-1,3-dienes with simple olefins. This protocol provides facile and atom-economic access to tetrahydropyridazines with good to excellent yields. Further investigations into a catalytic

Table 3. Substrate Scope for Hydrazones with **b2<sup>a</sup>**

entry	a	R	adduct	yield (%) <sup>b</sup>
1	<b>a2</b>	4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	<b>c29</b>	99
2	<b>a3</b>	4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	<b>c30</b>	99
3	<b>a4</b>	2-ClC <sub>6</sub> H <sub>4</sub>	<b>c31</b>	90
4	<b>a6</b>	4-BrC <sub>6</sub> H <sub>4</sub>	<b>c32</b>	66
5 <sup>c</sup>	<b>a12</b>	<i>n</i> -C <sub>11</sub> H <sub>23</sub>	<b>c33</b>	75

<sup>a</sup>General conditions: **a** (0.40 mmol), **b2** (3.0 equiv),  $K_2CO_3$  (2.0 equiv), and  $CH_2Cl_2$  (0.2 M), room temperature, 24 h. <sup>b</sup>Isolated yield. <sup>c</sup>**b2** (5.0 equiv), 36 h.

Scheme 3. Synthesis of **c1** on a Gram ScaleScheme 4. Transformation of **c1**

asymmetric version of this reaction and the extension of the methodology to other types of alkenes are ongoing.

## ■ ASSOCIATED CONTENT

### Supporting Information

General experimental procedures, characterization details, and <sup>1</sup>H and <sup>13</sup>C NMR spectra, IR spectra, and HRMS for new products. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Authors

\*E-mail: luosz@iccas.ac.cn.

\*E-mail: lvjian@iccas.ac.cn.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We thank the Natural Science Foundation of China (21390400, 21025208, 21202170, and 21472193) and the National Basic Research Program of China (2012CB821600) for financial support. S.L. is supported by the National Program of Top-

notch Young Professionals and CAS Youth Innovation Promotion Association.

## REFERENCES

- (1) (a) Bockholt, H.; Beale, J. M.; Rohr, J. *Angew. Chem., Int. Ed.* **1994**, *33*, 1648. (b) Grote, R.; Chen, Y.; Zeeck, A. *J. Antibiot.* **1988**, *41*, 595.
- (2) Cho, J. Y.; Kwon, H. C.; Williams, P. G.; Jensen, P. R.; Fenical, W. *Org. Lett.* **2006**, *8*, 2471.
- (3) (a) Combs, D. W.; Reese, K.; Phillips, A. *J. Med. Chem.* **1995**, *38*, 4878. (b) Combs, D. W.; Reese, K.; Cornelius, L. A. M.; Gunnet, J. W.; Cryan, E. V.; Granger, K. S.; Jordan, J. J.; Demarest, K. T. *J. Med. Chem.* **1995**, *38*, 4880. (c) Palmer, S.; Campen, C. A.; Allan, G. F.; Rybczynski, P.; Haynes-Johnson, D.; Hutchins, A.; Kraft, P.; Kiddoe, M.; Lai, M.-T.; Lombardi, E.; Pedersen, P.; Hodgen, G.; Combs, D. W. *J. Steroid Biochem. Mol. Biol.* **2000**, *75*, 33.
- (4) Rybczynski, P. J.; Combs, D. W.; Jacobs, K.; Shank, R. P.; Dubinsky, B. *J. Med. Chem.* **1999**, *42*, 2403.
- (5) Zhang, L.; Williams, M. A.; Mendel, D. B.; Escarpe, P. A.; Chen, X.; Wang, K.-Y.; Graves, B. J.; Lawton, G.; Kim, C. U. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 1751.
- (6) Lange, J. H. M.; den Hartog, A. P.; van der Neut, M. A.; van Vliet, B. J.; Kruse, C. G. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5675.
- (7) For a review, see: (a) Attanasi, O. A.; Crescentini, L. D.; Favi, G.; Filippone, P.; Mantellini, F.; Perrulli, F. R.; Santeusano, S. *Eur. J. Org. Chem.* **2009**, 3109. For recent examples, see: (b) Attanasi, O. A.; Favi, G.; Filippone, P.; Perrulli, F. R.; Santeusano, S. *Org. Lett.* **2009**, *11*, 309. (c) Attanasi, O. A.; Favi, G.; Filippone, P.; Mantellini, F.; Moscatelli, G.; Perrulli, F. R. *Org. Lett.* **2010**, *12*, 468. (d) Attanasi, O. A.; Favi, G.; Mantellini, F.; Moscatelli, G.; Santeusano, S. *Adv. Synth. Catal.* **2011**, *353*, 1519. (e) Lopes, S. M. M.; Brigas, A. F.; Palacios, F.; Lemos, A.; Pinho e Melo, T. M. V. D. *Eur. J. Org. Chem.* **2012**, 2152. (f) Hu, X.-Q.; Chen, J.-R.; Gao, S.; Feng, B.; Lu, L.-Q.; Xiao, W.-J. *Chem. Commun.* **2013**, *49*, 7905. (g) Hu, X.-Q.; Chen, J.-R.; Wei, Q.; Liu, F.-L.; Deng, Q.-H.; Beauchemin, A. M.; Xiao, W.-J. *Angew. Chem., Int. Ed.* **2014**, *53*, 12163. (h) Attanasi, O. A.; Crescentini, L. D.; Filippone, P.; Fringuelli, F.; Mantellini, F.; Matteuccib, M.; Piermattib, O.; Pizzo, F. *Helv. Chim. Acta* **2001**, *84*, 513. (i) D'Auria, M.; Racioppi, R.; Attanasi, O. A.; Mantellini, F. *Synlett* **2010**, 1363. (j) Lemos, A. In *Targets in Heterocyclic Systems – Chemistry and Properties*, Vol. 14; Attanasi, O. A., Spinelli, D., Eds.; Società Chimica Italiana: Rome, 2010; p 1. (k) Rossi, E.; Abbiati, G.; Attanasi, O. A.; Rizzato, S.; Santeusano, S. *Tetrahedron* **2007**, *63*, 11055. (l) Attanasi, O. A.; Favi, G.; Mantellini, F.; Mantenuto, S.; Moscatelli, G.; Nicolini, S. *Synlett* **2015**, 26, 193. For an example of the use of electron-poor alkenes, see: (m) Attanasi, O. A.; Bianchi, L.; D'Auria, M.; Mantellini, F.; Racioppi, R. *Curr. Org. Synth.* **2013**, *10*, 631.
- (8) (a) Chen, J.-R.; Dong, W.-R.; Candy, M.; Pan, F.-F.; Jörres, M.; Bolm, C. *J. Am. Chem. Soc.* **2012**, *134*, 6924. (b) Gao, S.; Chen, J.-R.; Hu, X.-Q.; Cheng, H.-G.; Lu, L.-Q.; Xiao, W.-J. *Adv. Synth. Catal.* **2013**, *355*, 3539. (c) Tong, M.-C.; Chen, X.; Li, J.; Huang, R.; Tao, H.; Wang, C.-J. *Angew. Chem., Int. Ed.* **2014**, *53*, 4680. (d) Guo, C.; Sahoo, B.; Daniliuc, C. G.; Glorius, F. *J. Am. Chem. Soc.* **2014**, *136*, 17402.
- (9) (a) Rogiers, J.; Wu, X.; Toppet, S.; Compernelle, F.; Hoornaert, G. *J. Tetrahedron* **2001**, *57*, 8971. (b) De Borggraeve, W. M.; Rombouts, F. J. R.; Van der Eycken, E. V.; Toppet, S. M.; Hoornaert, G. *J. Tetrahedron Lett.* **2001**, *42*, 5693. (c) Van der Eycken, E.; Appukkuttan, P.; De Borggraeve, W.; Dehaen, W.; Dallinger, D.; Kappe, C. O. *J. Org. Chem.* **2002**, *67*, 7904. (d) Stadler, A.; Yousefi, B. H.; Dallinger, D.; Walla, P.; Van der Eycken, E.; Kaval, N.; Kappe, C. O. *Org. Process Res. Dev.* **2003**, *7*, 707. (e) Rogiers, J.; De Borggraeve, W. M.; Toppet, S. M.; Compernelle, F.; Hoornaert, G. *J. Tetrahedron* **2003**, *59*, 5047. (f) Kaval, N.; Dehaen, W.; Kappe, C. O.; Van der Eycken, E. *Org. Biomol. Chem.* **2004**, *2*, 154. (g) Kamoune, L.; De Borggraeve, W. M.; Verbist, B. M. P.; Broeck, J. V.; Coast, G. M.; Compernelle, F.; Hoornaert, G. *Tetrahedron* **2005**, *61*, 9555. (h) Rodriguez, A. M.; Prieto, P.; de la Hoz, A.; Díaz-Ortiz, A. *Org. Biomol. Chem.* **2011**, *9*, 2371.
- (10) For selected examples: (a) Williams, C. L.; Chang, C.-C.; Do, P.; Nikbin, N.; Caratzoulas, S.; Vlachos, D. G.; Lobo, R. F.; Fan, W.; Dauenhauer, P. J. *ACS Catal.* **2012**, *2*, 935. (b) Do, P. T. M.; McAtee, J. R.; Watson, D. A.; Lobo, R. F. *ACS Catal.* **2013**, *3*, 41. (c) Chang, C.-C.; Green, S. K.; Williams, C. L.; Dauenhauer, P. J.; Fan, W. *Green Chem.* **2014**, *16*, 585. (d) Pacheco, J. J.; Davis, M. E. *Proc. Natl. Acad. Sci. U.S.A.* **2014**, *111*, 8363.
- (11) (a) Banks, R. E.; Harrison, A. C.; Haszeldine, R. N.; Orrell, K. G. *Chem. Commun.* **1965**, 3, 41. (b) Chung, Y.; Duerr, B. F.; McKelvey, T. A.; Nanjappan, P.; Czarnik, A. W. *J. Org. Chem.* **1989**, *54*, 1018. (c) Kakiuchi, K.; Yamaguchi, B.; Kinugawa, M.; Ue, M.; Tobe, Y.; Odaira, Y. *J. Org. Chem.* **1993**, *58*, 2797. (d) Takeshita, H.; Kawakami, H.; Ikeda, Y.; Mori, A. *J. Org. Chem.* **1994**, *59*, 6490.
- (12) (a) Lv, J.; Zhang, L.; Hu, S.; Cheng, J.-P.; Luo, S. *Chem.—Eur. J.* **2012**, *18*, 799. (b) Lv, J.; Zhong, X.; Cheng, J.-P.; Luo, S. *Acta Chim. Sin.* **2012**, *70*, 1518. (c) Lv, J.; Zhang, L.; Luo, S.; Cheng, J.-P. *Angew. Chem., Int. Ed.* **2013**, *52*, 9786. For a review, see: (d) Lv, J.; Luo, S. *Chem. Commun.* **2013**, 49, 847.
- (13) Sinha, M.; Dola, V. R.; Soni, A.; Agarwal, P.; Srivastava, K.; Haq, W.; Puri, S. K.; Katti, S. B. *Bioorg. Med. Chem.* **2014**, *22*, 5950.